All In MedTech

FDA Clearance Tracker · P120005-S090

DEXCOM G5 Mobile Continuous Glucose Monitoring System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 12, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 12, 2023

Approved

Time to decision

90 days

Received Oct 14, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P120005-S090
Device name
DEXCOM G5 Mobile Continuous Glucose Monitoring System
Applicant
Dexcom, Inc.
Applicant location
San Diego, CA
Received
Oct 14, 2022
Decided
Jan 12, 2023
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P120005

Device type

Device class
Class III

Every decision under product code MDS

FDA's approval statement

As written in FDA's record.

Approval to modify the prior inclusion criterion to the following: Clinical diagnosis of Type 1 or Type 2 diabetes with at least one (1) week of insulin initiation at time of study entry.

Source documents

Other decisions for Dexcom, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.